# Retraction: Abdallah MS, Ramadan AN, Omara‐Reda H, et al. Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neurosci. Ther. 2021;27:1540–1548 (https://doi.org/10.1111/cns.13731)

## TL;DR

This paper is a retraction of a study on cilostazol as an antidepressant due to data integrity issues.

## Contribution

The paper formally retracts a prior clinical trial due to concerns about data reliability.

## Key findings

- The study's data integrity was questioned by a third party.
- An investigation confirmed significant issues with the reported data.
- The journal's editor retracted the paper due to loss of confidence in the results.

## Abstract

Retraction: Abdallah MS, Ramadan AN, Omara‐Reda H, et al. Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neurosci. Ther. 2021;27:1540–1548 (https://doi.org/10.1111/cns.13731)

The above article, published online on September 21, 2021 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor‐in‐Chief, Xiaoming Hu, and John Wiley and Sons Ltd.

Following publication, multiple concerns were raised by a third party about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor‐in‐Chief no longer has confidence in the validity of the results presented in this article.